METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control advanced prostate cancer
Disease control Not yet recruitingThis early-stage trial tests the safety of combining a radioactive drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapy. Participants receive either the ra…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
Could an Alzheimer's drug fight prostate cancer?
Disease control Not yet recruitingThis study tests whether memantine hydrochloride, a drug used for Alzheimer's, can help treat advanced prostate cancer that has stopped responding to standard treatments. About 15 men with metastatic castration-resistant prostate cancer will take the drug alongside their usual th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Bin Xu • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug combo aims to control advanced breast cancer
Disease control Not yet recruitingThis study tests a new drug called ERW316, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer or other solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. A…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with a specific type of advanced prostate cancer that has stopped responding to standard treatments. It uses a special imaging agent to find cancer cells and then delivers targeted radiation to destroy them. The goal is to see if this combi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug trial aims to tame resistant prostate cancer
Disease control Not yet recruitingThis early-stage study tests a new drug called xaluritamig in 40 adults with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal is to check the drug's safety and how the body processes it. Participants must have cancer that has s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
CBD may offer new hope for End-Stage prostate cancer pain
Symptom relief Not yet recruitingThis study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. 58 participants will receive either CBD or a placebo three times daily for nine …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Regionshospital Nordjylland • Aim: Symptom relief
Last updated May 13, 2026 15:59 UTC